HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Line Between Beauty And Pharma Blurs As Both Chase Aesthetics Market

This article was originally published in The Rose Sheet

Executive Summary

As beauty firms seek credibility for their products through science-based claims and drug companies move into the consumer aesthetics market, the boundary between prescription and over-the-counter is growing fuzzier
Advertisement

Related Content

Reliant Links With Philips To Develop Laser Skin-Care Device For Home Use
Clinique, Allergan To Create Skin Care For Botox, Dermal Filler Recipients
Clinique, Allergan To Create Skin Care For Botox, Dermal Filler Recipients
CEW Partners With NPD To Make 2008 Beauty Awards More Exclusive
CEW Partners With NPD To Make 2008 Beauty Awards More Exclusive
Sales & Earnings In Brief
Stiefel Uses Coffee Berry, Connetics Buy To Close In On Aesthetic Market
Elizabeth Arden To Co-Market Prevage Cream Under Allergan Deal
Elizabeth Arden To Co-Market Prevage Cream Under Allergan Deal
Advertisement
UsernamePublicRestriction

Register

RS014655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel